Literature DB >> 24430504

Interactions between Tau and α-synuclein augment neurotoxicity in a Drosophila model of Parkinson's disease.

Bidisha Roy1, George R Jackson.   

Abstract

Clinical and pathological studies have suggested considerable overlap between tauopathies and synucleinopathies. Several genome-wide association studies have identified alpha-Synuclein (SNCA) and Tau (MAPT) polymorphisms as common risk factors for sporadic Parkinson's disease (PD). However, the mechanisms by which subtle variations in the expression of wild-type SNCA and MAPT influence risk for PD and the underlying cellular events that effect neurotoxicity remain unclear. To examine causes of neurotoxicity associated with the α-Syn/Tau interaction, we used the fruit fly as a model. We utilized misexpression paradigms in three different tissues to probe the α-Syn/Tau interaction: the retina, dopaminergic neurons and the larval neuromuscular junction. Misexpression of Tau and α-Syn enhanced a rough eye phenotype and loss of dopaminergic neurons in fly tauopathy and synucleinopathy models, respectively. Our findings suggest that interactions between α-Syn and Tau at the cellular level cause disruption of cytoskeletal organization, axonal transport defects and aberrant synaptic organization that contribute to neuronal dysfunction and death associated with sporadic PD. α-Syn did not alter levels of Tau phosphorylated at the AT8 epitope. However, α-Syn and Tau colocalized in ubiquitin-positive aggregates in eye imaginal discs. The presence of Tau also led to an increase in urea soluble α-Syn. Our findings have important implications in understanding the cellular and molecular mechanisms underlying α-Syn/Tau-mediated synaptic dysfunction, which likely arise in the early asymptomatic phase of sporadic PD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24430504      PMCID: PMC4014195          DOI: 10.1093/hmg/ddu011

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   5.121


  123 in total

1.  Coexpression of GSK-3beta corrects phenotypic aberrations of dorsal root ganglion cells, cultured from adult transgenic mice overexpressing human protein tau.

Authors:  R Nuydens; G Van Den Kieboom; C Nolten; C Verhulst; P Van Osta; K Spittaels; C Van den Haute; E De Feyter; H Geerts; F Van Leuven
Journal:  Neurobiol Dis       Date:  2002-02       Impact factor: 5.996

2.  Snaring the function of alpha-synuclein.

Authors:  Nancy M Bonini; Benoit I Giasson
Journal:  Cell       Date:  2005-11-04       Impact factor: 41.582

3.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

Authors:  M H Polymeropoulos; C Lavedan; E Leroy; S E Ide; A Dehejia; A Dutra; B Pike; H Root; J Rubenstein; R Boyer; E S Stenroos; S Chandrasekharappa; A Athanassiadou; T Papapetropoulos; W G Johnson; A M Lazzarini; R C Duvoisin; G Di Iorio; L I Golbe; R L Nussbaum
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

4.  Antibodies to horseradish peroxidase as specific neuronal markers in Drosophila and in grasshopper embryos.

Authors:  L Y Jan; Y N Jan
Journal:  Proc Natl Acad Sci U S A       Date:  1982-04       Impact factor: 11.205

5.  Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins.

Authors:  J M Jenco; A Rawlingson; B Daniels; A J Morris
Journal:  Biochemistry       Date:  1998-04-07       Impact factor: 3.162

6.  Regulated interactions of the norepineprhine transporter by the actin and microtubule cytoskeletons.

Authors:  Alexis M Jeannotte; Anita Sidhu
Journal:  J Neurochem       Date:  2008-03-03       Impact factor: 5.372

7.  Induction of the phase II detoxification pathway suppresses neuron loss in Drosophila models of Parkinson's disease.

Authors:  Kien Trinh; Katherine Moore; Paul D Wes; Paul J Muchowski; Joyoti Dey; Laurie Andrews; Leo J Pallanck
Journal:  J Neurosci       Date:  2008-01-09       Impact factor: 6.167

8.  C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease.

Authors:  A Abraha; N Ghoshal; T C Gamblin; V Cryns; R W Berry; J Kuret; L I Binder
Journal:  J Cell Sci       Date:  2000-11       Impact factor: 5.285

9.  Paraquat, but not maneb, induces synucleinopathy and tauopathy in striata of mice through inhibition of proteasomal and autophagic pathways.

Authors:  Jonathan Wills; Joel Credle; Adam W Oaks; Valeriy Duka; Jae-Hoon Lee; Jessica Jones; Anita Sidhu
Journal:  PLoS One       Date:  2012-01-23       Impact factor: 3.240

10.  Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease.

Authors:  A Ebneth; R Godemann; K Stamer; S Illenberger; B Trinczek; E Mandelkow
Journal:  J Cell Biol       Date:  1998-11-02       Impact factor: 10.539

View more
  35 in total

1.  α-Synuclein modifies mutant huntingtin aggregation and neurotoxicity in Drosophila.

Authors:  Gonçalo M Poças; Joana Branco-Santos; Federico Herrera; Tiago Fleming Outeiro; Pedro M Domingos
Journal:  Hum Mol Genet       Date:  2014-12-01       Impact factor: 6.150

2.  A Preliminary Study on Investigation of Serum α-Synuclein and Tau Protein Levels in Children with Attention Deficit Hyperactivity Disorder.

Authors:  Ihsan Cetin; Seref Simsek
Journal:  Indian J Clin Biochem       Date:  2016-08-03

Review 3.  α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies.

Authors:  Yvette C Wong; Dimitri Krainc
Journal:  Nat Med       Date:  2017-02-07       Impact factor: 53.440

Review 4.  Drug discovery from natural products - Old problems and novel solutions for the treatment of neurodegenerative diseases.

Authors:  Urmila Maitra; Cayman Stephen; Lukasz M Ciesla
Journal:  J Pharm Biomed Anal       Date:  2021-12-24       Impact factor: 3.935

Review 5.  Interactions Between α-Synuclein and Tau Protein: Implications to Neurodegenerative Disorders.

Authors:  Xuling Li; Simon James; Peng Lei
Journal:  J Mol Neurosci       Date:  2016-09-15       Impact factor: 3.444

Review 6.  Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.

Authors:  Elvira Valera; Brian Spencer; Eliezer Masliah
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

7.  Genetic Variants of Microtubule Actin Cross-linking Factor 1 (MACF1) Confer Risk for Parkinson's Disease.

Authors:  Xin Wang; Nuomin Li; Nian Xiong; Qi You; Jie Li; Jinlong Yu; Hong Qing; Tao Wang; Heather J Cordell; Ole Isacson; Jeffery M Vance; Eden R Martin; Ying Zhao; Bruce M Cohen; Edgar A Buttner; Zhicheng Lin
Journal:  Mol Neurobiol       Date:  2016-03-28       Impact factor: 5.590

Review 8.  Drosophila as an In Vivo Model for Human Neurodegenerative Disease.

Authors:  Leeanne McGurk; Amit Berson; Nancy M Bonini
Journal:  Genetics       Date:  2015-10       Impact factor: 4.562

9.  Initiation of Parkinson's disease from gut to brain by δ-secretase.

Authors:  Eun Hee Ahn; Seong Su Kang; Xia Liu; Guiqin Chen; Zhentao Zhang; Bindu Chandrasekharan; Ashfaqul M Alam; Andrew S Neish; Xuebing Cao; Keqiang Ye
Journal:  Cell Res       Date:  2019-10-24       Impact factor: 25.617

10.  Interplay between tau and α-synuclein liquid-liquid phase separation.

Authors:  Anna Siegert; Marija Rankovic; Filippo Favretto; Tina Ukmar-Godec; Timo Strohäker; Stefan Becker; Markus Zweckstetter
Journal:  Protein Sci       Date:  2021-01-28       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.